Wantong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wantong Li has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Bradley W. Blaser
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
19 shared publications - Alexander He
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
18 shared publications - Altan Turkoglu
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
18 shared publications - Annika Chura
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
18 shared publications - Britten K. Gordon
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
18 shared publications - James S. Blachly
The Ohio State University, Columbus, Ohio, United States
18 shared publications
Latest Publications
- 20 October 2026
- Published by The Company of Biologists in Development
Vcam1 in endothelial and stromal cells regulates hematopoietic stem cell contact with the niche
Hematopoietic stem and progenitor cells (HSPCs) are essential for differentiation into all blood cell types. In mammals, the interaction between HSPCs and the fetal liver niche during development is critical for stem cell maturation. Integrin alpha 4 (Itga4) on HSPCs and vascular cell adhesion molecule (Vcam1) on niche cells are critical for HSPC colonization of the fetal liver (FL). Itga4 and Vcam1 also function in the zebrafish equivalent of the FL, the caudal hematopoietic tissue (CHT), however, the specific niche cells that express Vcam1 remain unclear. Using multiple approaches, including fluorescent in situ hybridization, we found Vcam1 is expressed in endothelial cells (ECs) and mesenchymal stromal cells (MSCs), but not macrophages. Time-lapse live imaging of itga4 mutants showed the Itga4-Vcam1 axis is not required for guiding HSPCs into the CHT niche but is required for their retention. Our results show that Itga4 on HSPCs, and Vcam1 on ECs and MSCs, are involved in CHT niche retention.
- 20 October 2026
- Published by The Company of Biologists in Development
Vcam1 in endothelial and stromal cells regulates hematopoietic stem cell contact with the niche
Hematopoietic stem and progenitor cells (HSPCs) are essential for differentiation into all blood cell types. In mammals, the interaction between HSPCs and the fetal liver niche during development is critical for stem cell maturation. Integrin alpha 4 (Itga4) on HSPCs and vascular cell adhesion molecule (Vcam1) on niche cells are critical for HSPC colonization of the fetal liver (FL). Itga4 and Vcam1 also function in the zebrafish equivalent of the FL, the caudal hematopoietic tissue (CHT), however, the specific niche cells that express Vcam1 remain unclear. Using multiple approaches, including fluorescent in situ hybridization, we found Vcam1 is expressed in endothelial cells (ECs) and mesenchymal stromal cells (MSCs), but not macrophages. Time-lapse live imaging of itga4 mutants showed the Itga4-Vcam1 axis is not required for guiding HSPCs into the CHT niche but is required for their retention. Our results show that Itga4 on HSPCs, and Vcam1 on ECs and MSCs, are involved in CHT niche retention.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S6. Supporting data for Figure 3. Expression of selected T cell phenotypic markers.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S6. Supporting data for Figure 3. Expression of selected T cell phenotypic markers.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S7: Genes expressed in CD16+ monocytes
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S7: Genes expressed in CD16+ monocytes
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S4. Supporting data for Figure 1. Expression of genes related to BCR signaling by B cells was aggregated by patient type and timepoint.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S4. Supporting data for Figure 1. Expression of genes related to BCR signaling by B cells was aggregated by patient type and timepoint.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S3: Differential gene expression analysis for IBS- and IBR-enriched clusters
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S3: Differential gene expression analysis for IBS- and IBR-enriched clusters
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S1. Supporting data for Figure 1. A. Distribution of reference cell type identities across major cell clusters (partitions). B. Expression of partition top markers.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S1. Supporting data for Figure 1. A. Distribution of reference cell type identities across major cell clusters (partitions). B. Expression of partition top markers.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental table S4: Gene set enrichment analysis
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental table S4: Gene set enrichment analysis
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S2: Gene modules and top markers
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S2: Gene modules and top markers
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S1: Sequencing metrics for each sample
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Table S1: Sequencing metrics for each sample
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S5. Supporting data for Figure 3. A. Individual T and NK cell labels transferred via Seurat. B. T and NK cell subclusters. C. Proportion of reference cell type labels attributed to subclusters after aggregation. D. Classification of T and NK cell subclusters by differential representation analysis. E. Gene set enrichment analysis comparing the IBS-enriched CD4 TCM cluster to the IBR-enriched TCM cluster (top), and the IBS-enriched CD4 TCM cluster to the CD4 Naïve Cluster. Gene sets used were GSE11057_NAIVE_VS_MEMORY_CD4_TCELL_UP and HALLMARK_TNFA_SIGNALING_VIA_NFKB, respectively. F. TCR diversity according to ibrutinib response and timepoint (Shannon’s Diversity; *: p < 0.05, Wilcoxon test).
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
Supplemental Figure S5. Supporting data for Figure 3. A. Individual T and NK cell labels transferred via Seurat. B. T and NK cell subclusters. C. Proportion of reference cell type labels attributed to subclusters after aggregation. D. Classification of T and NK cell subclusters by differential representation analysis. E. Gene set enrichment analysis comparing the IBS-enriched CD4 TCM cluster to the IBR-enriched TCM cluster (top), and the IBS-enriched CD4 TCM cluster to the CD4 Naïve Cluster. Gene sets used were GSE11057_NAIVE_VS_MEMORY_CD4_TCELL_UP and HALLMARK_TNFA_SIGNALING_VIA_NFKB, respectively. F. TCR diversity according to ibrutinib response and timepoint (Shannon’s Diversity; *: p < 0.05, Wilcoxon test).